1stOncology™: Cancer Intelligence Service – Page 13115 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Molecular Templates to Present a Corporate Overview at the Cowen & Company 39th Annual and the Oppenheimer & Co. 29th Annual Health Care Conferences

On March 5, 2019 Molecular Templates, Inc. (Nasdaq: MTEM), a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in oncology, reported that management will provide a corporate overview at the Cowen & Company 39th Annual Health Care Conference, and the Oppenheimer & Co., 29th Annual Health Care Conference (Press release, Molecular Templates, MAR 5, 2019, http://ir.mtem.com/news-releases/news-release-details/molecular-templates-present-corporate-overview-cowen-company [SID1234534043]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Cowen & Company 39th Annual Health Care Conference
Date: Monday, March 11
Time: 3:30pm Eastern Time
Webcast: http://wsw.com/webcast/cowen52/mtem/

Oppenheimer & Co 29th Annual Health Care Conference
Date: Tuesday, March 19
Time: 8:00am Eastern Time
Molecular Templates is focused on the discovery, development and commercialization of next-generation immunotoxins called Engineered Toxin Bodies (ETBs) for the treatment of cancers and other serious diseases. For additional information, please visit Molecular Templates’ website at www.mtem.com.

Synlogic Announces Fourth Quarter and Full Year 2018 Conference Call and Webcast

On March 5, 2019 Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, reported that the Company will release its fourth quarter and full year 2018 financial results before the market opens on Tuesday, March 12, 2019 (Press release, Synlogic, MAR 5, 2019, View Source [SID1234534030]). The press release will be followed by a conference call at 8:00 am ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a corporate update.

The conference call dial-in numbers are (844) 815-2882 for domestic callers and (213) 660-0926 for international callers. The conference ID number for the call is 2181868. Participants may access the live webcast via a link on the Synlogic website in the Events Calendar of the Investors and Media section. For those unable to participate in the conference call or webcast, a replay will be available for 30 days on the Company’s website.

Five Prime Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference

On March 5, 2019 Five Prime Therapeutics, Inc.(NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics reported that Aron Knickerbocker, Chief Executive Officer of Five Prime Therapeutics, will present at the 39TH Annual Cowen Healthcare Conference onWednesday, March 13, 2019 at 8:40am ET (Press release, Five Prime Therapeutics, MAR 5, 2019, http://investor.fiveprime.com/news-releases/news-release-details/five-prime-therapeutics-present-cowen-and-company-39th-annual [SID1234534022]).

The presentation will be webcast and may be accessed at the "Events & Presentations" section of the Company’s website at: View Source Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.

BIOGEN TO PRESENT AT THE COWEN 39TH ANNUAL HEALTH CARE CONFERENCE

On March 5, 2019 Biogen Inc. (Nasdaq:BIIB) reported that it will present at the Cowen 39th Annual Health Care Conference (Press release, Biogen, MAR 5, 2019, http://investors.biogen.com/news-releases/news-release-details/biogen-present-cowen-39th-annual-health-care-conference [SID1234534021]). The webcast will be live on Monday, March 11, at 11:20 a.m. ET. To access the live webcast, please visit Biogen’s Investors section at View Source An archived version of the webcast will be available following the presentation.

Alkermes’ Corporate Presentation to be Webcast at the Cowen and Company 39th Annual Health Care Conference

On March 5, 2019 Alkermes plc (Nasdaq: ALKS) reported that its corporate presentation will be webcast live at the Cowen and Company 39th Annual Health Care Conference on Tuesday, Mar. 12, 2019 at 8:40 a.m. ET (12:40 p.m. GMT) from Boston (Press release, Alkermes, MAR 5, 2019, View Source;p=RssLanding&cat=news&id=2390204 [SID1234534020]). The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction, multiple sclerosis and oncology. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.